Japanese pharmaceutical companies some of the most sophisticated and cash-rich in the world are shopping abroad for targets to enrich their drug pipelines and counter the uncertain outlook for sales in Japan. But sellers are still insisting on hefty price-tags, despite slowing economic growth and depressed equity markets.
On the face of it, Japan’s greying population looks like good news for the country's pharma businesses. More than one-fifth of Japanese people are over 65 and, according to the CIA World Factbook, the country has the world’s third longest life expectancy at 82 years. But these positive demographics are not providing Japanese drug-makers with the earnings bonanza they may have hoped...
¬ Haymarket Media Limited. All rights reserved.
